Table 3. The effect of YD on serum pro-inflammatory cytokines in atherosclerotic rats.
| Group | Dosage (g/kg) | TNF-α (ng/L) | IL-1β (ng/mL) | CRP (ng/mL) |
|---|---|---|---|---|
| con | — | 20.9 ± 1.1** | 0.55 ± 0.03** | 5.59 ± 0.43** |
| AS | — | 47.0 ± 3.4 | 0.74 ± 0.12 | 8.74 ± 0.72 |
| Ator | 0.01 | 26.4 ± 9.5** | 0.59 ± 0.16** | 6.19 ± 0.36** |
| YD-2.0 | 2.0 | 33.9 ± 3.3** | 0.64 ± 0.10** | 5.64 ± 0.50** |
| YD-1.0 | 1.0 | 26.8 ± 5.4** | 0.64 ± 0.07** | 6.04 ± 0.47** |
| YD-0.5 | 0.5 | 26.3 ± 3.9** | 0.67 ± 0.12* | 6.07 ± 0.52* |
Number of experimental animals (N), interleukin-1β (IL-1β), and tumor necrosis factor alpha (TNF-α). Yindanxinnaotong (YD), atorvastatin(Ator).
Results are expressed as mean ± SD, n = 12.
*p < 0.05 vs atherosclerosis model group, **p < 0.01 vs the atherosclerosis model group.